LifeSci Capital Initiates Coverage of BioTime, Inc.

Lead Product Renevia is Being Developed for Several Dermatological Applications;

Report Available Here: http://www.lifescicapital.com/equity-research/biotime/

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of BioTime Inc. (NYSE: BTX), a clinical-stage biotechnology company focused on regenerative medicine. The Company is developing technologies that utilize stem cells, biomaterials, lab-generated cells and tissues, and biologics to treat various conditions and diseases.

BioTime’s lead asset is Renevia, an adipose tissue replacement device being developed for use in various aesthetic dermatological applications. The Company will initially pursue approval in the EU for the treatment of facial HIV-related lipoatrophy (HRLA), a disorder characterized by fat loss in HIV infected patients related to the use of antiretroviral therapies (ART). Renevia is an implantable matrix that delivers autologous adipose tissue-derived cells to restore texture while promoting soft tissue regeneration over the long term. BioTime is currently conducting a pivotal clinical trial with Renevia for the treatment of facial HRLA, and expects top-line data in the second quarter of 2017.

BioTime is also pursuing the development of OpRegen, a proprietary injection of human embryonic stem cell (hESC) derived retinal pigment epithelium (RPE) cells for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Dry AMD is characterized by late-onset degeneration of RPE and photoreceptor cells in the macula of eye. OpRegen is an allogeneic, or off-the-shelf therapy that aims to integrate hESC-RPE cells into the subretinal space to replace atrophied RPE cells and restore visual function in AMD patients. OpRegen has been granted Fast Track designation by the FDA, which allows for more frequent meetings with the agency regarding development plan and trial design, eligibility for accelerated approval and priority review, and rolling NDA submission. BioTime is currently conducting a Phase I/II dose-escalation study with OpRegen for the treatment of dry AMD with GA, and expects to report novel data in the first half of 2017.

In a 47 page Initiation Report, LifeSci Capital describes the Company’s treatments for HRLA and AMD, how these products are differentiated from other therapies, and the market opportunities for each indication, as well as other potential applications.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on BioTime as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 453854